Canaccord Genuity Group Has Lowered Expectations for TELA Bio (NASDAQ:TELA) Stock Price

TELA Bio (NASDAQ:TELA) had its price objective reduced by equities researchers at Canaccord Genuity Group from $4.00 to $2.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective suggests a potential upside of 171.74% from the company’s current price.

TELA has been the subject of several other research reports. Lake Street Capital restated a “buy” rating on shares of TELA Bio in a research report on Monday, December 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of TELA Bio in a research report on Thursday, January 22nd. Finally, Loop Capital set a $3.00 target price on shares of TELA Bio in a research note on Monday, December 1st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $2.85.

TELA Bio Price Performance

NASDAQ:TELA traded down $0.03 during trading hours on Wednesday, reaching $0.74. 68,819 shares of the company’s stock were exchanged, compared to its average volume of 170,914. The company has a quick ratio of 2.62, a current ratio of 3.30 and a debt-to-equity ratio of 26.65. The company has a market capitalization of $29.69 million, a P/E ratio of -0.81 and a beta of 0.88. The business’s 50-day simple moving average is $0.85 and its two-hundred day simple moving average is $1.14. TELA Bio has a 12 month low of $0.67 and a 12 month high of $2.20.

TELA Bio (NASDAQ:TELA) last announced its earnings results on Tuesday, March 24th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $20.87 million for the quarter, compared to analyst estimates of $21.04 million. TELA Bio had a negative return on equity of 272.13% and a negative net margin of 50.61%. Sell-side analysts expect that TELA Bio will post -1.37 EPS for the current fiscal year.

Hedge Funds Weigh In On TELA Bio

Several hedge funds have recently bought and sold shares of TELA. XTX Topco Ltd bought a new position in shares of TELA Bio in the fourth quarter worth about $48,000. WealthTrust Axiom LLC increased its position in shares of TELA Bio by 39.1% during the fourth quarter. WealthTrust Axiom LLC now owns 322,588 shares of the company’s stock valued at $381,000 after purchasing an additional 90,650 shares during the period. Renaissance Technologies LLC raised its stake in shares of TELA Bio by 101.4% in the 4th quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock valued at $152,000 after buying an additional 64,800 shares in the last quarter. Essex Woodlands Management Inc. raised its position in TELA Bio by 87.7% in the fourth quarter. Essex Woodlands Management Inc. now owns 7,714,709 shares of the company’s stock worth $9,103,000 after purchasing an additional 3,604,000 shares in the last quarter. Finally, Perkins Capital Management Inc. raised its holdings in shares of TELA Bio by 67.6% in the fourth quarter. Perkins Capital Management Inc. now owns 1,397,418 shares of the company’s stock valued at $1,649,000 after buying an additional 563,490 shares during the last quarter. 94.35% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting TELA Bio

Here are the key news stories impacting TELA Bio this week:

• Positive Sentiment: Reported record revenue growth for Q4 and full-year 2025, showing improvement in sales momentum that management says underpins its commercial transformation. GlobeNewswire Release Yahoo Highlights
• Positive Sentiment: Company guided to at least ~8% revenue growth in 2026 and emphasized advancing its commercial transformation, which gives a concrete growth target investors can model. Seeking Alpha: Guidance
• Neutral Sentiment: Third‑party notes and transcripts provide detail on the call and results for parsing management commentary and execution milestones; useful for due diligence but not new headline items. InsiderMonkey Transcript MSN Transcript
• Neutral Sentiment: Short-interest reports flagged a “large increase” in March in some feeds, but the published figures appear inconsistent (showing zero shares / NaN), so treat those data points with caution until verified. (No reliable link available.)
• Negative Sentiment: Reported EPS of -$0.16 narrowly missed one consensus reference point of -$0.155 (a slight miss that can still trigger negative sentiment in a thin‑traded, low‑float name). Market reaction reflects sensitivity to even small earnings variances. Seeking Alpha Transcript
• Negative Sentiment: Small market cap, low share price, and the company trading below longer‑term moving averages make the stock more volatile and vulnerable to downside on mixed results; investors will watch cadence of commercial execution and cash runway closely. (See company metrics in trading summary supplied to you.)
• Negative Sentiment: Zacks noted the Q4 loss but framed it against estimates (reported -$0.16 vs Zacks -$0.18), highlighting how different benchmarks can create mixed headlines and short‑term volatility. Zacks Note

TELA Bio Company Profile

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.